Podcasts about Asymptomatic

Chris and Nathan both have new online courses for you to check out.  Nathan's course Rebuild: BSI Management https://runningmatekc.com/rebuild-bone-stress-injury-online-course/ Chris's Course: Clinical Running Essentials https://chrisjohnsonpt.com/clinical-running-essentials/ In this episode, Chris and Nathan dive into  2:00 Does an absensce of pain mean you can start running?7:00 What if a physician gives the runners a green light?11:50 The research on asymptomatic BSIs12:45 Nathan's phases of BSI rehab17:15 What if running is too important to the patient?21:00 Avoiding distractions in recovery23:00 The George article32:00 Navigating symptoms during BSI rehab39:00 Should patients avoid social media? Warden article https://pubmed.ncbi.nlm.nih.gov/33962529/ George article https://pubmed.ncbi.nlm.nih.gov/39141251/ Asymptomatic tibial BSIs https://pubmed.ncbi.nlm.nih.gov/15333349/

This week's topics include treating hot flashes in breast cancer survivors, a blood test for detecting colorectal cancer, exercise to improve survival after colorectal cancer treatment and CAR-T therapy for solid tumors.Program notes:0:40 CAR-Ts for solid tumors1:40 Advanced gastric or gastroesophageal cancer2:40 Cytokine release syndrome3:22 Exercise after treatment for colorectal cancer4:23 Disease free survival superior5:23 Currently not much exercise6:23 Potential mechanisms7:10 Treating hot flashes in breast cancer survivors8:10 Neurokinin receptors9:12 A blood test to screen for colorectal cancer10:12 Asymptomatic adults11:12 Will not replace FIT or screening colonoscopy12:12 Survival advantage due to polypectomy13:19 End

In this episode, Therese Markow and Dr. Joshua Weitz discuss his book "Asymptomatic: The Silent Spread of COVID-19 and the Future of Pandemics" and his work in understanding the risk of COVID spread from as early as spring of 2020. He highlights the double-edged sword of asymptomatic infections, discusses what governments could do to help mitigate at-risk populations, and what we, as individuals, can do to help keep everyone safe. Dr. Weitz criticizes early predictions of COVID-19's disappearance by mid-2020, attributing the error to underestimated infections and behavioral changes. He emphasizes the importance of public health measures, vaccination, and testing, especially in vulnerable populations. Finally, Dr. Weitz talks about the role of asymptomatic transmission in future pandemics and the need for proactive public health investments.    Key Takeaways: Not having symptoms doesn't mean that you never had COVID-19. Nearly 50% of cases in early 2020 were asymptomatic (though that number varies by age).  There was not one single group of modelers trying to make sense of the data coming out of the pandemic. As such, different projections can come out even from the same pandemic information. For infectious diseases, our behavior is correlated with the risk.  COVID is not the flu. COVID is not gone, and we now have a double seasonal burden from both flu and COVID. If everyone is asymptomatic or it was always mild, we wouldn't worry. We wouldn't have stopped things or been so upset just by cases or infections; it was the severe ones and the number of severe cases that dictated the approach to control, as the transmission potential by asymptomatic individuals was not considered.  "The double-edged sword is good news, in some sense, for individuals, but it's bad news for populations, because many more people can be infected. They're contagious and interact with more people. When we try to think from a public health perspective, not just a personal health perspective, then we have to be concerned." —  Dr. Joshua Weitz   Connect with Dr. Joshua Weitz: Professional Bio: https://biology.umd.edu/people/dr-joshua-weitz  LinkedIn: https://www.linkedin.com/in/joshua-weitz-5866599/  Substack: http://joshuasweitz.substack.com/    Website: https://weitzgroup.umd.edu/   Book: Asymptomatic: The Silent Spread of COVID-19 and the Future of Pandemics https://www.press.jhu.edu/books/title/53730/asymptomatic   Connect with Therese: Website: www.criticallyspeaking.net Threads: @critically_speaking Email: theresemarkow@criticallyspeaking.net Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.  

Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-how-to-manage-asymptomatic-aria/27043/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: B. Joy Snider, MD, PhD Guest: Jerome A. Barakos, MD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Resident GP & CEO of Proactive Health Solutions, Dr Fundile Nyati, shines the spotlight on the new global challenge of asymptomatic TB (aTB) in light of World Tuberculosis Day on Monday 24 March. See omnystudio.com/listener for privacy information.

Vanessa Spina is a Sport Nutrition Specialist (SNS) and the Best Selling author of Keto Essentials. She is a researcher who studied biomedical science at the University of Toronto, an international speaker and host of the wildly popular Optimal Protein Podcast, ranked in the Top 20 podcasts in the Nutrition category in the USA and globally #1-20. It has been nominated twice as a top 3 Best Podcast at the Metabolic Health Summit.  Vanessa founded Ketogenic Girl in 2015 with online audience of over half a million. Vanessa has created three innovative wellness products. The Tone device, a breath ketone analyzer which measures acetone, the ketone detected on the breath. The second is a new red light therapy line called the Tone LUX Collection. The third is a supplement line called Tone that includes Tone Protein, a protein powder that is scientifically formulated to initiate Muscle Protein Synthesis in every serving with the addition of leucine, and the new Tone Collagen which has clinical studies (RCTs) proving its effectiveness.  She has been featured as a nutrition expert in articles published in the Orlando Sentinel, Eat This, Parade, Reader's Digest and more. Instagram: @ketogenicgirl @optimalproteinpodcast @tonedevice @thetonelux Twitter: @ketogenicgirl Website: Www.ketogenicgirl.com Timestamps: 00:00 Trailer 01:12 Introduction 04:09 Children's innate eating wisdom 07:44 Rising awareness of food quality 10:29 European dietary habits and trends 15:02 Carnivore diet ended my food obsession 17:49 Revamped keto focus on ketones 19:03 Asymptomatic progress and protein satiety 22:26 MCT and ketone supplements for focus 27:36 Ketones: alternative brain fuel 31:53 High-fat foods and nutrition 33:23 Balanced diet preference over carnivore 38:02 Drunken attempt to avoid onions 41:05 New book on high-protein diets 44:28 Whey protein and insulin response 46:23 Whey protein isolate benefits 51:02 Red meat misconceptions persist 52:55 Where to find Vanessa Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Today, we're speaking to Dr Sam Merriel, a GP, and NIHR Academic Clinical Lecturer in General Practice based at the University of Manchester.Title of paper: Factors affecting prostate cancer detection through asymptomatic PSA testing in primary care in England: Evidence from the 2018 National Cancer Diagnosis AuditAvailable at: https://doi.org/10.3399/BJGP.2024.0376Asymptomatic, informed choice prostate specific antigen (PSA) testing occurs in primary care in the UK in the absence of a national prostate cancer screening programme. This study shows that four fifths of prostate cancers are diagnosed following symptomatic presentation rather than from asymptomatic PSA testing. There is a 13-fold variation in asymptomatic PSA test detected prostate cancer between English GP practices, without clear explanatory practice-level factors. Patient factors amongst men diagnosed with prostate cancer, including ethnicity, age, deprivation, and multi-morbidity, have a significant impact on the likelihood of being diagnosed following asymptomatic PSA testing.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

Send us a textShort Summary: Insider's look at the COVID-19 pandemic response from a seasoned epidemiologist, unraveling myths and lessons with straightforward science.About the guest: Martin Kulldorff, PhD is an epidemiologist and biostatistician with decades of experience in infectious disease monitoring and vaccine safety. He was formerly a professor at Harvard Medical School. Note: Podcast episodes are fully available to paid subscribers on the M&M Substack. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: Dr. Martin Kulldorff discusses the COVID pandemic response, reflecting on the controversial Great Barrington Declaration, which opposed lockdowns in favor of protecting the vulnerable. They explore the virus's fatality rates, asymptomatic spread, and vaccine efficacy, contrasting textbook epidemiology with real-world decisions. He critiques institutional failures, like the CDC's misleading claims. He shares optimism for future pandemics with better leadership and public awareness.Key Takeaways:Lockdowns ignored basic public health principles, causing collateral damage like missed cancer screenings, while Sweden's focused protection approach led to lower excess mortality.Early data showed COVID's risk was 1000x higher for older people, yet lockdowns didn't prioritize them, unlike textbook strategies.Asymptomatic spread made containment impossible, unlike Ebola, where isolation works due to clear symptoms.Natural immunity was downplayed despite 2500 years of evidence, leading to wasted vaccines on those already immune.CDC falsely claimed vaccines stopped transmission, eroding trust when people got sick anyway, fueling vaccine skepticism.mRNA vaccine boosters lack proper trials, and their long-term effects need rigorous study, not assumptions.Kulldorff's new Journal of the Academy of Public Health pushes open peer review to rebuild trust in science.Related episode:M&M #100: Infectious Disease, Epidemiology, Pandemics, Health Policy, COVID, Politicization Support the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

Recent randomized trials, including EARLY TAVR, AVATAR, RECOVERY, and EVOLVED, suggest benefits of early aortic valve replacement (AVR) in asymptomatic severe aortic stenosis (AS). Early AVR reduces stroke, heart failure hospitalizations, and cardiovascular events, with a trend toward improved survival. The data support shifting from clinical surveillance to early intervention?

The EVOLVED trial investigated whether early aortic valve intervention could improve outcomes in asymptomatic patients with severe aortic stenosis and myocardial fibrosis. The randomized, multicenter study of 224 patients found no significant difference in all-cause mortality or unplanned aortic stenosis-related hospitalizations between early intervention and guideline-directed conservative management. However, early intervention was associated with lower rates of NYHA class II-IV symptoms and fewer unplanned hospitalizations. The trial highlights the potential symptomatic benefits of early intervention but underscores the need for further research to assess long-term outcomes.

EVOLVED: Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis and Left Ventricular Myocardial Fibrosis

Contributor: Aaron Lessen, MD Educational Pearls: Many patients present to the ED with elevated BP Many are referred from outpatient surgery centers or present after an elevated measurement at home Persistent questions on the best way to treat these patients The AHA published a scientific statement on the management of elevated BP in the acute care setting Hypertensive emergencies: SBP/DBP >180/110–120 mm Hg with evidence of new or worsening target-organ damage Includes aortic dissection or subarachnoid hemorrhage  Require aggressive treatment Asymptomatic markedly elevated inpatient BP: SBP/DBP >180/110–120 mm Hg without evidence of new or worsening target-organ damage AND asymptomatic elevated inpatient BP: SBP/DBP ≥130/80 mm Hg without evidence of new or worsening target-organ damage No benefits to urgent treatment in the ED, but there are harms to treating patients in this manner These patients do not require IV medications  Provide reassurance and instructions on following up with their PCP to manage their BP in the outpatient setting Removed the term “hypertensive urgency” References Bress AP, Anderson TS, Flack JM, et al. The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association. Hypertension. 2024;81(8). doi:https://doi.org/10.1161/hyp.0000000000000238 Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3  Donate: https://emergencymedicalminute.org/donate/  

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from October 26-November 1, 2024.

The JournalFeed podcast for the week of Oct 21-25, 2024.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Monday Spoon Feed:This article emphasizes the difference between hypertensive emergency and asymptomatic elevated blood pressure (BP). While hypertensive emergency requires prompt treatment to lower BP, treatment of asymptomatic elevated BP in acute care settings may be harmful. Tuesday Spoon Feed: This was a multi-hospital retrospective study of patients who presented to the emergency department with severe hypertension without end organ damage. The authors found that the 1 year rate of major adverse cardiovascular events (MACE) was 15.5%.

It can be difficult to determine whether you should treat undifferentiated hypertension or not. Many clinicians are distracted the number rather than focusing on the patient in front of them. Asymptomatic hypertension, in particular, is often benign. In fact, treating asymptomatic hypertension in a patient who a primary medical history of hypertension can harm them. In this podcast, we discuss these adverse effects related to blood pressure physiology, acute versus chronic hypertension, and how you can determine whether anti-hypertensives or other forms of therapy are indicated. Get CE hours for our podcast episodes HERE! -------------------------------------------- Twitter @heavyhelmet Facebook @heavyliesthehelmet Instagram @heavyliesthehelmet Website heavyliesthehelmet.com Email contact@heavyliesthehelmet.com Disclaimer: The views, information, or opinions expressed on the Heavy Lies the Helmet podcast are solely those of the individuals involved and do not necessarily represent those of their employers and their employees. Heavy Lies the Helmet, LLC is not responsible for the accuracy of any information available for listening on this platform. The primary purpose of this series is to educate and inform, but it is not a substitute for your local laws, medical direction, or sound judgment. --------------------------------------------  Crystals VIP by From The Dust | https://soundcloud.com/ftdmusic Music promoted by https://www.free-stock-music.com

In this episode, researchers explore how asymptomatic versus symptomatic hypertension affects heart failure patients on sacubitril valsartan, finding that both types are linked to worse outcomes, but the drug's benefits remain strong, suggesting clinicians should avoid stopping treatment based solely on blood pressure.

Discover the Secret to Peaceful, Predictable, & PMS Free Periods Here! If you enjoyed today's episode, make sure you leave a rating and review! Want to support the show even more? Grab Berri a Coffee! Mentioned in today's episode: Prenatal Berri's Taking Recommended Website for Pregnancy Support Equipment Berri's Breast Pump Berri's Compression Socks Berri's Pregnancy Support Band Connect with Berri Berri's YouTube Berri's Instagram Berri's TikTok

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on the association of Cardiac Troponin T with coronary atherosclerosis in asymptomatic primary prevention in people with HIV.

Wudupdoe! This week, topics include - Coworker drama - Amazon delivery gone bad - Getting fit - Covid is still around eh? and more

بیماری‌های منتقل شونده با رابطه‌ی جنسی، در افراد بی‌علامت

This episode discusses four recent articles about lymphogranuloma venereum (LGV) including the effectiveness of a 7-day doxycycline course and the increasing prevalence of asymptomatic LGV in the era of HIV PrEP. View episode transcript and references at www.std.uw.edu.This podcast is dedicated to an STD [sexually transmitted disease] review for health care professionals who are interested in remaining up-to-date on the diagnosis, management, and prevention of STDs. Editor and host Dr. Meena Ramchandani is an Assistant Professor of Medicine at the University of Washington (UW) and Program Director of the UW Infectious Diseases Fellowship Program. 

Our Vascular Surgery Oral Board Audio Review includes 72 high-yield scenarios that cover the majority of the VSCORE topics designed for Vascular Surgeons by Vascular Surgeons.   Scenarios are 5 to 7 minutes long and include a variety of tactics and styles. If you are able to achieve this level of performance in your preparation you are sure to pass the oral exam with flying colors. The second part introduces high-yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy-to-understand teaching that covers the most confusing topics we face as vascular surgeons. We are confident you will find this unique, dual format approach a highly effective way to prepare for the test. Learn more about the full set of 72 scenarios here: https://app.behindtheknife.org/course-details/vascular-surgery-oral-board-audio-review Our Vascular Surgery Oral Board Book is available on Amazon here: https://www.amazon.com/dp/B0CZ8ZBF83 Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss… Recurrent acute anterior uveitis is associated with Māori ethnicity and HLA-B27 disease, and moderate vision loss is associated with shorter time to first recurrence JAK1 inhibitors may reduce the rate of treatment failure in inflammatory uveitis when compared to patients receiving placebo Asymptomatic vitreoretinal lymphoma (VRL) associated with primary CNS lymphoma exhibits lower rates of anterior segment involvement, vitritis, and subretinal infiltrates when compared to primary vitreoretinal lymphoma and symptomatic vitreoretinal lymphoma associated with primary CNS disease A study identifies patient factors that influence the presence of non-retinal hemorrhage ocular abnormalities in infants

Commentary by Dr. Candice Silversides

In this episode of The SHEA Podcast, SHEA Journal Club Chair and moderator Hannah Imlay is joined by guests Jennifer Cihlar and David Cluck to discuss two of the most impactful articles reviewed by the journal club this year. The first article, "Bacteremia From a Presumed Urinary Source in Hospitalized Adults With Asymptomatic Bacteriuria" by Advani SD, Ratz D, Horowitz JK, et al., examines the clinical implications of asymptomatic bacteriuria in hospitalized adults. The second article, "Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study" by Soto CL, Hsu AJ, Lee JH, et al., explores optimal antibiotic treatment durations for these challenging infections. Join us for an in-depth discussion on the findings and clinical impacts of these studies.

Commentary by Dr. Candice Silversides

Foreign interference documents meeting pushed, Nude beach disaster, Asymptomatic and surveillance for asymptomatic stuff, What are your feelings on a draft? Hard no from me dawg, Trump talks about bitcoin and cbdc, Invasion of the west is getting big push back, Sign Up for the Full Show Locals (daily video) https://canadapoli2.locals.com/ Spotify https://podcasters.spotify.com/pod/show/canadapoli/subscribe Private Full podcast audio https://canadapoli.com/feed/canadapoliblue/ Buy subscriptions here (daily video and audio podcast): https://canadapoli.com/canadapoli-subscriptions/

Commentary by Dr. Candice Silversides

How can we be sure viruses don't exist? What about the “patient 0” who transmits diseases at the start of nearly every pandemic? And do germs and microorganisms exist? What's making us sick, if not these things? Dr. Samantha and  Dr. Mark Bailey are the authors of “The Final Pandemic” and today they answer frequently asked questions about viruses. They explain how the medical community has been unable to prove that viruses make us sick or that they even exist in the first place. They also answer questions about the use of antibiotics and about whether germ theory and terrain theory can possibly coexist. Visit Sam and Mark's website: drsambailey.com Become a member of the Weston A. Price Foundation Members can get 5 free brochures "Timeless Principles of Healthy Traditional Diets" in private members space here Check out our sponsors: Nutrition Therapy Institute and Polyface Farms Two Days of Truth summit

This episode focuses on a fascinating and often overlooked topic; asymptomatic bacteriuria. This condition, characterized by the presence of bacteria in the urine without symptoms of an infection, poses unique challenges in the field of antimicrobial stewwardship. We'll explore what asymptomatic bacteriuria is, who is most affected, and why it's important to differentiate this condition from symptomatic infections. Our goal is to uncover how understanding and managing asymptomatic bacteriuria can lead to more efffective antibiotic use and ultimately, better patient outcomes. Listen in to learn more.

In this JCO Article Insights episode, Subodh Selukar summarized findings from the original article published in the January 2024 JCO issue: “The Importance of Low and Moderate Grade Adverse Events on Patients' Treatment Experience and Treatment Discontinuation” and accompanying editorial “Patient Experience, Adverse Event Reporting, and Clinical Trial Design”. The summary provides information regarding low and moderate grade adverse events and the patient experience in clinical trials. TRANSCRIPT Welcome to the JCO Article Insights episode for the January 2024 issue of Journal of Clinical Oncology. This is Subodh Selukar, your host, and today I will be providing a summary on 2 articles focused on low and moderate grade adverse events. The first article, titled “The Importance of Low and Moderate Grade Adverse Events on Patients' Treatment Experience and Treatment Discontinuation” by Dr. O'Connell and colleagues, investigated low and moderate grade adverse events and the patient experience in clinical trials. Their article is accompanied by an editorial entitled “Patient Experience, Adverse Event Reporting, and Clinical Trial Design” by Dr. Neuman.  In clinical trials, a standardized system for reporting adverse events is the Common Terminology Criteria for Adverse Events (or “CTCAE”) established by the NCI, the United States National Cancer Institute. The CTCAE categorizes adverse events at 5 severity grades across 26 system organ classes. However, some clinical trials may only report adverse events at grade 3 or higher, with one possible rationale being that low and moderate grades are unlikely to affect patient safety or key trial endpoints. In Dr. O'Connell's article, the team investigated how the numbers of grade 1 and 2 adverse events related to patient self-reported side-effect burden and treatment discontinuation. To do this, they analyzed data from the Phase 3 trial E1912 conducted by ECOG-ACRIN comparing two treatments for chronic lymphocytic leukemia. They chose this trial as an example because the study data included all adverse event grades throughout the duration of treatment for each patient. The authors studied side-effect burden based on GP5, which is the fifth item in the FACT-G subscale in the Functional Assessment of Cancer Therapy. GP5 rates the patient's agreement with the statement “I am bothered by side effects of treatment” in the past 7 days, and it has previously been connected with adverse event grade and treatment discontinuation. For treatment discontinuation, the authors focused on those discontinuations that were recorded as being due to “adverse events, side effects or complications.” They found that, for each adverse event grade, there were, on average, more adverse events in cycles that ended with a patient discontinuing treatment compared to other cycles. Next, they used Bayesian models to assess how the numbers of grade 1 and grade 2 adverse events in a treatment cycle were associated with the odds of higher side-effect bother and odds of treatment discontinuation, after adjusting for cycle number, treatment and occurrence of grade 3 or higher adverse events within the cycle. Baseline GP5 was also included in the models, and these models also accounted for the inclusion of multiple cycles for each patient. When adjusting for baseline GP5, treatment, cycle and presence of grade 3 or 4 adverse events, both the number of grade 1 and the number of grade 2 adverse events were each strongly associated with increasing side-effect bother. The adjusted odds of treatment discontinuation were also higher with more grade 2 adverse events. However, with the same adjustment variables, the odds of treatment discontinuation were actually lower with larger numbers of grade 1 adverse events. In their primary analysis, they focused on adverse events that were attributed to treatment, so they excluded non-treatment-related adverse events from the counts. Sensitivity analyses including these adverse events have similar conclusions but with a weaker magnitude of effect. They attributed this to issues like existing adverse events not causing new bother. Next, the authors analyzed whether symptomatic versus asymptomatic adverse events affected these results by re-fitting the models and separating the predictors into numbers of asymptomatic and symptomatic grade 1 or 2 adverse events. In these results, they found no evidence for associations between numbers of asymptomatic adverse events at any grade and side-effect bother. On the other hand, they found strong evidence for associations with symptomatic adverse events of grade 2 and 3 or higher both for side-effect bother as an outcome and with treatment discontinuation. Asymptomatic grade 2 adverse events were associated with treatment discontinuation but not side-effect bother, and symptomatic grade 1 adverse events were associated with side-effect bother but not treatment discontinuation.  ·       The authors conclude that adverse events of all grades, especially symptomatic adverse events, should be recorded regularly in cancer clinical trials. Formal patient reported outcomes are not typically collected as frequently as adverse events are recorded, so identifying patients with a high number of lower grade adverse events could be used to facilitate early supportive care to improve patient quality of life and reduce the likelihood for treatment discontinuation. ·       They also highlight their result identifying lower odds of treatment discontinuation with larger numbers of grade 1 adverse events. They provide one explanation that patients may perceive grade 1 adverse events being associated with treatment efficacy, but this perception changes with higher grades.  In their call to collect more lower grade adverse events, the authors acknowledge that recording more adverse events may be time-consuming and burdensome for sites and recommend cost-benefit analyses to develop future guidelines. ·       This balance between the benefits and costs of increased adverse event data collection is the focus of Dr. Neuman's editorial. Dr. Neuman acknowledges that Dr. O'Connell's article provides a convincing argument for how low grade adverse event information is valuable, but notes the clinical trial context that current efforts at the NCI are to more efficiently conduct cancer research, which could be supported by streamlining data collection. ·       Requiring the collection of low grade adverse events could have important impacts to trial logistics. Due to the high volume of low grade adverse events, reporting all low grade events could delay reporting higher grade and more serious adverse events; and it would require an increase in the effort of clinical trial research staff, which would be difficult if not accompanied by an increase in reimbursement to sites. ·       Dr. Neuman suggests 3 approaches to balance the costs and benefits of collecting low and moderate grade adverse events. First, investigators could consider limiting low-grade adverse event reporting to the experimental arm. The standard of care regimens may not always have low-grade adverse event data available, but this may still be justified when there is extensive clinical experience with the standard of care. However, this approach is only practical when the experimental arm is not blinded. ·       A second approach for moderating the effort in collecting low-grade adverse events is to limit collection to symptomatic adverse events, connecting with Dr. O'Connell's example E1912 dataset. This approach could be addressed by prespecifying types of symptomatic adverse events that would be most impactful during the trial design phase. ·       Dr. Neuman's third suggestion is to plan for a follow-up study after the phase 3 trial to collect low-grade adverse event data and their impact on patients' experiences and treatment discontinuation. This would be beneficial by only requiring low-grade adverse events in an experimental regimen that has successfully passed phase 3. However, a new study would require funding and site enthusiasm, which could prove challenging. ·       Overall, Dr. Neuman emphasizes that investigators should develop trial-specific considerations and engage with the relevant stakeholders during study design. Because of the complexity of adverse events in these patient populations, the best uses of grade 1-2 adverse events will likely continue to develop in the future. In their article, Dr. O'Connell's team studied grade 1 and 2 adverse events as separate predictors, but I would be curious to know how the accumulation and trajectory of these adverse events affect the patient experience. For example, even if the severity does not rise to grade 3, an increasing trend in a patient's adverse event severities could signal the treating physician to modify study dose or to discontinue the treatment. I'm not sure if that type of information was available in their trial E1912, but perhaps that could be a factor to consider for the future. And, of course, it will be important to assess how these grade 1-2 adverse events relate to the patient experience in different studies, especially across different cancer patient populations, acknowledging that this is inherently challenging to study because the data to inform this research is not universally available. As Dr. Neuman indicates, trial-specific goals and expertise will remain critical when considering the data collection for a given trial.  That concludes this episode of JCO Article Insights regarding a summary of the article “The Importance of Low and Moderate Grade Adverse Events on Patients' Treatment Experience and Treatment Discontinuation” by Dr. O'Connell and colleagues and the editorial entitled “Patient Experience, Adverse Event Reporting, and Clinical Trial Design” by Dr. Neuman. This is Subodh Selukar. Thank you for your attention and stay tuned for the next episode of JCO Article Insights.

Greetings sports fans! This week we bring you arguably John Waters' most widely viewed film: Serial Mom (1994). Pitch perfect performances really sell this tale of a middle class white lady from the Baltimore 'burbs who erases anyone that gets on her bad side. Plus, per usual, we shit on some of our favorite Hollywood bastards to hate, reference porn and praise Kathy Bates bravura boobies (RIP). Typical. Let's All Go to the Lobby (B.A.N. remix) T.J. Tallie | Asymptomatic Lethality: Cooper, COVID-19, and the Potential for Black Death +++++ Intro: by Professor Ping available on BandcampOutro: Doja Cat performing Paint the Town Red --- Support this podcast: https://podcasters.spotify.com/pod/show/zandkmoviepod/support

The Vasopressor & Inotrope Handbook: Amazon Affiliate Link (I will earn an extra small commission) and Signed Copies. Show Notes: eddyjoemd.com/asymptomatic-catheter-related-thrombosis/ Explore the often-overlooked issue of asymptomatic catheter-related thrombosis (CRT) in ICU patients on The Saving Lives Podcast. This episode delves into a revealing study published in the Annals of Intensive Care, uncovering the incidence, risk factors, and implications of asymptomatic CRT. Join us for a thought-provoking discussion that challenges traditional beliefs and sheds light on crucial aspects of catheter management in critical care. TrueLearn Link: ⁠⁠⁠⁠⁠⁠⁠https://truelearn.referralrock.com/l/EDDYJOEMD25/⁠⁠⁠⁠⁠⁠⁠ Discount code: EDDYJOEMD25 This Podcast was edited using Descript: ⁠⁠⁠⁠https://www.descript.com?lmref=BGOxjQ⁠⁠⁠⁠ Citation: Abbruzzese C, Guzzardella A, Consonni D, Turconi G, Bonetti C, Brioni M, Panigada M, Grasselli G. Incidence of asymptomatic catheter-related thrombosis in intensive care unit patients: a prospective cohort study. Ann Intensive Care. 2023 Oct 19;13(1):106. doi: 10.1186/s13613-023-01206-w. PMID: 37858003; PMCID: PMC10587047. Link to Article --- Support this podcast: https://podcasters.spotify.com/pod/show/eddyjoemd/support

Case Discussion 100: Congenital right coronary anomaly

 In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Jason Andrade from the University of British Columbia, Vancouver, Canada. They discuss all aspects of asymptomatic and device-detected atrial fibrillation. If you enjoy the show, please leave us a podcast review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 or wherever you get your podcasts - it's really helpful. Link to published paper: https://heart.bmj.com/content/early/2023/07/28/heartjnl-2023-322428?rss=1 

Owwwww my hips hurt! Hip pain in runners is not uncommon, and physical therapist Dr. Sarah Louie joins the show to talk about hips, running, and what you need to know to "bulletproof" your hips as a runner! -What are some misunderstandings runners have about hip injuries? -The form and function of how our hips work -Why you need more than clamshells to bulletproof your hips -Ruling out bone stress injuries -Injuries from morphology differences -Strength training that WORKS for stronger hips -Considerations for pregnant and post-partum runners -Asymptomatic labral tears: what next? -And more! Sarah Louie is a Fellowship Trained Doctor of Physical Therapy and return-to-run coach who specifically helps women runners with hip pain return to run comfortably and confidently through the EmpowHER Hip Program.  https://www.instagram.com/dr.sarah_thehipdoc/

TWiV reviews approvals of the first gene therapy for severe hemophilia A in adults and a monoclonal antibody to prevent RSV respiratory disease in babies and toddlers, and a common allele of HLA that mediates asymptomatic SARS-CoV-2 infection through pre-existing T cell immunity due to previous exposure to common cold coronaviruses. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server First gene therapy for hemophilia A approved (FDA) Luxurna, gene therapy for vision loss (FDA) Anti-RSV monoclonal antibody approved (FDA) Trial of single-dose Nirsevimab (NEJM) Letters read on TWiV 1028 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Phoenix hits 110 degrees for the 19th day in a row, setting national record Brianne – James Webb Telescope One Year Anniversary Photo Kathy – Drone awards photos Alan – WHO Film Festival winners Vincent – Thinking, Fast and Slow by Daniel Kahneman Listener Picks David – The Mass Extinction Debates: A Science Communication Odyssey Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Join veterinary cardiology specialists, Kieran Borgeat and Jose Novo Matos, in a discussion of feline heart disease. This is the first of a two-part series opening special, covering how to approach heart murmurs in cats, when it may be useful to use blood tests in screening, and how to facilitate performing a heart scan in feline patients.

This week Kate, Gary, Henry and Mark talk about bempedoic acid for the prevention of ASCVD, the polypill and cognitive decline in the elderly, post-exposure prophylaxis in persons at high risk of STIs, asymptomatic CAD and subsequent AMI risk. And do you know how long ankle arthroplasties last?

Looking 4 Healing Radio with Dr. Bryan Ardis, Nichola Burnett, Dr. Jana Schmidt, and Dr. Henry Ealy – In this episode of Looking 4 Healing Radio, Dr. Bryan, Nichola, Dr. Jana & Dr. H talk about the history of natural medicine and what blew them away in their research. Listen in as these four Healers talk history, how it has repeated itself with the lie of asymptomatic transmission, and what you can...

Commentary by Dr. Valentin Fuster

In episode 536, Mike and James talk about 4 questions – Is any bacteriuria associated with altered mental state? – Does treating ASB improve/prevent clinical outcomes? – Does treating ASB improve altered mental state? – Do antibiotic reduction interventions for ASB affect patient outcomes? Tune in to find out the answers. Show Notes 1) Tools […]

Find out if ultra-short course (two days) antibiotics work for pneumonia, if acetazolamide improves diuretic efficiency in acute decompensated heart failure, should we prescribe psilocybin (magic mushrooms) to treat alcohol use disorder, and if removal of asymptomatic kidney stones decreases the incidence of future events! Time to fill your plate with a fresh stack of hotcakes! Drs. Paul Williams (@PaulNWilliamz), Rahul Ganatra (@rbganatra), and Matt Watto (@doctorwatto) catch up on recent practice-changing articles and guidelines!  Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Show Segments Intro, disclaimer Ultra-short Antibiotics for Pneumonia,  Acetazolamide for acute heart failure exacerbations,  Psilocybin for AUD, Asymptomatic Kidney Stone Removal Outro Credits Written by: Nora Taranto MD; Rahul Ganatra MD, MPH; Paul Williams, MD, FACP, Matthew Watto MD, FACP Hosted by: Rahul Ganatra MD, MPH; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewer: Rahul Ganatral MD, MPH Technical Production: Pod Paste

On this weeks episode, I give you my final thoughts on COVID-19.Topics Discussed:3:11 - Asymptomatic spread and why viruses don't want to kill their hosts9:18 - PCR testing fiasco10:59 - Reports of Covid in the water supply prior to 2020 and people with antibodies to Covid prior to 201912:16 - Social media censorship that I experienced from the beginning15:18 - Why diabetics, males, and smokers were getting hit that hardest from Covid20:51 - I explain ACE receptors & Cytokine storms27:13 - How viruses act inside the obese body36:20 - What we did to our senior citizensDownload my FREE BOOK and get on my email list. Follow me on my Substack BlogSponsored by: The Dr. Tyna StoreGet 10% OFF my Main Store and my CBD Store here.Further Listening:Muscle is MedicineToxic Legacy: Glyphosate, Deuterium and the COVID vaccine Get full access to Dr. Tyna Show Podcast & Censorship-Free Blog at drtyna.substack.com/subscribe

The misplaced idea that asymptomatic Covid cases drove viral spread, was the cornerstone of public health authorities enacting draconian mandates and highly destructive lockdowns. Now, data from a new study covering 42 countries shows people with asymptomatic Covid infections are 68% less likely to pass the virus on, highlighting another failure of public health authorities.#AsymptomaticSpread #CovidMisinformation #Fauci #Birx #CDC #FDA #NIH